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Abstract
The antimalarial drug pyronaridine (PND) was tested for its potential as an anticancer
drug. After exposing cancerous (17) and non-cancerous (2) cell lines to PND, PND was found to
exhibit consistent and potent cytotoxic activity at low micromolar (μM) concentrations. PND
elicited phosphatidylserine externalization, mitochondrial depolarization, and DNA
fragmentation in both the triple-negative MDA-MB-231 breast cancer and HL-60 leukemia cell
lines. In addition, PND treatment altered cell cycle progression in both cancer cells. Subsequent
DNA mobility-shift assays, UV-Visible spectroscopic titrations, and circular dichroism (CD)
experiments revealed that PND intercalates with DNA. Furthermore, transcriptome signatures
findings suggested that PND might act as a topoisomerase II inhibitor. Topoisomerase inhibition
assays showed that PND is a bona fide topoisomerase II inhibitor. In-vivo studies suggest that
PND hinders tumor progression. Combination studies of PND with known anticancer drugs
revealed higher cytotoxicity against cancer cells than individual drug administration. Although
an attempt was made to create PND-resistant breast cancer cells (MDA-MB-231), only cells with
slight resistance were generated. However, PND is cytotoxic to a paclitaxel-resistant breast
cancer cell line. The findings presented in this study indicate that PND has the potential as a
repurposed drug for cancer therapy.
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Chapter 1: Introduction
1.1 Cancer
Cancer can be defined as the uncontrolled division of a subset of the body’s cells1.
Cancer development can be viewed as a multistep process, which involves mutation, selection of
cells that have an increased capacity to proliferate, survive, invade, and ultimately metastasize2.
The abnormal proliferation of the different types of cell in the body can result in distinct types of
cancer1. Current clinical cancer treatments involve surgery, radiation, and chemotherapy2. These
treatments have worked for some patients, but others have suffered reoccurrence. While
reoccurrence data is hard to come by mainly because it is not collected in cancer registries or
other population-based data sources3, it is proven that some reoccurrence happens in part by
cancer cells becoming drug resistant4.
1.2 Hispanics and cancer
As part of the Border Biomedical Research Center (BBRC in UTEP) the goal is to
promote and support translational research to reduce health disparities in the region and across
the country. There are higher rates of premature morbidity and mortality in Hispanic cancerrelated health disparities in the southwest border region. Predominantly, breast cancer is the
primary cancer type and a leading cause of cancer death in Hispanic women5. In 2019, Texas had
the second-highest estimated number of new female breast cancer cases in the U.S.6. It is
unknown how many of these cases will undergo complete remission, and there is a possibility
that for some, the cancer will reoccur locally or distantly (metastasis)7. Moreover, the
reoccurrence of breast cancer represents the principal cause of breast-cancer related deaths8.
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Many factors can cause recurrence. In particular, an alarmingly increasing concern has been drug
resistance throughout the years. The search for new therapies to overcome this constantly
emerging issue has led many to search for drugs that can be repurposed as anticancer agents.
1.3 Drug Repurposing
An attractive proposition to combat drug resistance in cancer has been drug repurposing
using approved drugs to treat other unintended diseases9. There are various benefits to using a
drug that has been previously used to treat other illnesses. The risk of failure is lower, the time
frame for drug development can be reduced, and there is less of a financial investment9. This
strategy can be beneficial not only to all those who have drug-resistant tumors/cancers but also
those needing new therapies. In addition, repurposed drugs have the possibility to be more
economically available to those in low-income socioeconomic groups who will benefit by
lowering the financial burden of cancer therapies10. Thus, it is advantageous to investigate the
potential that repurposed drugs have to become anticancer treatments.
1.4 Pyronaradine Tetraphosphate
The drug pyronaridine (PND) is a benzonaphthyridine derivative initially synthesized in
1970 at the Institute of Chinese Parasitic Disease and has been used in China for over 30 years
for the treatment of malaria11. Previous reports indicated that PND inhibits β-hematin formation,
promoting β-hematin-induced red blood cell lysis based on in vitro studies of Plasmodium
falciparum K112. It was also suggested that PND could be an inhibitor of DNA topoisomerase II
of P. falciparum, provoking the formation of a PND-DNA topoisomerase II-DNA complex13.
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Although PND did not generate the formation of protein-DNA complexes, PND did inhibit P.
falciparum parasitic DNA topoisomerase II activity in vitro11.
In addition to its studies with P. falciparum, PND was tested in combination with
doxorubicin (DOX) on multidrug-resistant (MDR) K562/A02 and MCF-7/ADR human cancer
cells and found to increase the sensitivity of cells to doxorubicin14. It is important to note that the
MCF-7/ADR cells used in those studies are not derived from the original MCF-7 breast cancer
cell line but instead were subsequently determined to be derived from the NCI/ ADR-RES
ovarian cancer cell line a derivative of OVCAR-815. The growth inhibitory effects of PND were
tested on several cancer cell lines, but the mechanism of action was not determined in this or in
earlier work from the same group14,16. PND was also found to exhibit the same DOX sensitizing
effect in mice carrying the same human MDR tumor xenografts (K562/A02 and MCF-7/ADR
cells) and did not exhibit toxicity to treated mice14. A recent report, it was demonstrated that
nanorods containing both PND and DOX could efficiently kill MDR MCF-7/ADR cells17.
However, in the previous reports, PND was only administered in combination with DOX, and
therefore it could not be determined if PND had an effect by itself14,16. Since the mechanism by
which PND exerts cell death was not previously explored, nor was it tested as a single agent, we
sought to determine PND’s activity in cancer cells.
1.5 Research Rationale
There are various approaches for drug discovery. A more traditional approach over the
past couple of years has involved the use of novel compounds and techniques such as highthroughput drug screening (HTS). This method involves the screening of large chemical libraries
for activity against biological targets18. While our lab mainly focuses on screening novel
3

compounds for enhanced cytotoxicity and selectivity against cancerous cells, this project
introduces a different drug discovery approach, the repurposing initiative. Drug repurposing has
gained attention as a productive approach for drug discovery19. Most importantly, drug
repurposing benefits have increased its use in the search for new anticancer therapies. The longterm goal of this research is to potentially repurpose Pyronaridine Tetraphosphate (PND) an
antimalarial drug, into an anticancer drug for the clinical arena. In the proposed project, we test
the hypothesis that pyronaridine (PND) will induce cell death in cancer cells. We also seek to
understand its mode of action and address the possibility of it becoming a potential anticancer
drug.
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Chapter 2: Evaluation And Characterization Of PND’s Anticancer Activity
2.1 Evaluating Activity of PND on a Panel of Cancer Cell Lines
2.1.1 Assessment of Cytotoxicity Induced by PND
To analyze the potential cytotoxic activity of PND (Figure 1), the Differential Nuclear
Staining (DNS) assay, which was validated for high-throughput screening (HTS) using live-cell
bio-imaging assay, was utilized20. For this assay, cells were seeded at 10,000 cells/well density in
a 96-well plate in 100 μl of culture media, incubated overnight, and treated with a gradient of
PND concentrations for 72 h. Two hours before imaging, two fluorescent nucleic acid
intercalators were added to each well, Hoechst 33342 and Propidium iodide (PI; Invitrogen), at a
final concentration of 1 μg/ml each. Hoechst stains all of the cells (total living and dead),
whereas PI, an impermeable dye to living cells, only stains dead cells with compromised
plasmatic membrane and high permeability. Montages of 2 by 2 images were captured directly
from each individual well of the culture plates by using a multi-well plate reader IN Cell 2000
analyzer, an HTS, and a high-content analysis (HCA) system (GE Healthcare Life Sciences,
Pittsburgh, PA). The following controls were included in every single plate: PBS as
solvent/vehicle control, hydrogen peroxide as a positive control for cytotoxicity, and untreated
cells to determine the background of toxicity due to cell manipulation and intrinsic factors
usually associated with the culture protocol. Each experimental data point, as well as controls,
was assessed in triplicates. Cytotoxic concentration 50% (CC50) values were calculated based on
a linear interpolation equation as previously described21. CC50 is defined as the PND
concentration required to disrupt the plasma membrane integrity of 50% of the cell population,
as compared with solvent-treated cells22.
5

Pyronaridine
Tetraphosphate (PND)

Figure 1. The chemical structure of Pyronaridine Tetraphosphate (PND)

Seventeen human cancer cell lines and two non-cancerous control cell lines (MCF-10A
and Hs-27; Table 1) were analyzed via DNS. For each individual cell line, dose-response curves
were created, also using the DNS assay, to determine the CC50 of PND on these cell lines. In
general, PND exerted potent cytotoxicity on all cells tested with consistent CC50 values at low
micromolar concentrations that ranged from 1.6 μM to 9.4 μM (Table 1). After testing a PNDconcentration gradient effect on both the MDA-MB-231 triple-negative breast cancer and the
HL-60 acute promyelocytic leukemia cell lines revealed CC50 values of 1.6 μM and 1.9 μM,
respectively (Figure 2A and 2B). In all these assays, untreated cells were included in determining
if cell death occurred in the absence of PND treatment due to manual manipulation and/or
incubation period. Solvent-treated cells were also used as a control for non-specific cell death
and for normalization purposes, and H2O2- treated cells were used as positive controls for
cytotoxicity (Figure 2). PND exerted significant selective cytotoxicity (SCI) index on four out of
six of breast cancer cell lines tested, MDA-MB-231, MDA-MB-231 LM2, MDA-MB-468, and
MCF-7 with SCI values of 4.13, 2.54, 3.88, and 4.13, respectively, as compared with its noncancerous breast MCF-10A cells (Table 1). Interestingly, the SCI values (<1) were not favorable
on T47D and HCC-70 with values below 1 (Table 1). In addition, the highest SCI value on
6

leukemia/lymphoma cells tested corresponded to the HL-60 cell line with an SCI value of 3.5
(Table 1). Additionally, PND exhibited an SCI value of 3 and 3.3, for Ramos and Jurkat cells,
respectively, but poor selectivity was noticed for the CEM cell line (Table 1). Good selectivity
was detected on the melanoma cell line (SCI = 3.2) and two of the three ovarian cancer lines
tested (SCI = 3.9). However, poor selectivity (<2.0) was detected on the pancreatic and lung
cancer lines (Table 1). Since PND exhibited low CC50 values and showed significant selectivity
(SCI >3) on both MDA-MB-231 and HL-60 cell lines, they were both selected for further
analyses. Furthermore, since there are more limited therapies to triple-negative breast cancers
(TNBCs), we have focused our characterization on the TNBC MDA-MB-231 cell line with the
hope of adding another possible treatment to these types of cancers.

Figure 2. Representative PND dose-response curves were utilized to determine the CC50 values. For these analyses, cells were
exposed for 72 h to PND, and cell viability was determined via the DNS assay. As an example, MDA-MB-231 (A) and HL-60
(B) were treated with a PND concentration gradient, as indicated on the x-axis, while the percentage of cytotoxicity (dead cells)
is shown on the y-axis. In this series of experiments, several controls were included: untreated cells and cells treated with the
PBS diluent alone (0.5% v/v) were used as negative controls, while 1 mM H2O2 was used as a positive control of cytotoxicity.
Each experimental point represents the mean of four replicas and error bars their corresponding standard deviation. Cytotoxic
concentration 50% (CC50) in micromolar (μM) units is defined as the concentration of PND required to perturb the plasma
membrane of 50% of the cells after 72 h of incubation.
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Table 1. PND cytotoxic concentration 50% (CC50) and selective cytotoxic index (SCI) on a panel of human cell lines
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2.2 Evaluating Apoptosis Induced by PND
2.2.1 Assessment of Phosphatidylserine Externalization Induced by PND
Phosphatidylserine (PS) externalization is an early feature of apoptosis induction that can
be readily detected with the high-affinity PS ligand annexin V–FITC via flow cytometry23,24,25.
Cells were seeded in 24-well plates at a density of 100,000 for adherent MDA-MB- 231 and
200,000 HL-60 cells in 1 ml of culture media. After overnight incubation, cells were treated with
PND, and incubated for an additional 24 h. For MDA-MB-231 cells, unattached cells were
harvested in an ice-cold tube, while adhered cells were detached by using HyQtase (Thermo
Fisher) and incubated for 5 min at 37 ̊C. Both unattached and detached cells harvested from
each individual well were washed with ice-cold PBS and centrifuged at 260 xg for 5 min. HL-60
cells were centrifuged directly after the incubation period as they grow in suspension. Cells were
then stained with a mixture of annexin V-FITC and PI in 100 μl of binding buffer and incubated
on ice in the dark for 15 minutes, following the manufacturer’s instructions (Beckman Coulter).
Lastly, the cells were resuspended in 400 μl of ice-cold binding buffer and analyzed by flow
cytometry (Cytomics FC500; Beckman Coulter). For this series of experiments, cells treated with
PBS, as solvent control; treated with H2O2, as a positive control of cytotoxicity; and untreated
were included and processed in parallel. For each sample, 10,000 events/cells were collected and
analyzed using CXP software (Beckman Coulter). Both the experimental samples and their
controls were processed similarly and assessed in triplicate. The sum of both early and late stages
of apoptosis was calculated to obtain the total percentage of apoptotic cells.

9

Figure 3. PND induced phosphatidylserine externalization on HL-60 (A) and MDA-MB-231 (B) cancer cells after 24 h of
incubation. The cell death mechanism was studied after double staining of cells with annexin V-FITC and PI and monitored via
flow cytometry. (A-B) The total percentages of cells undergoing apoptosis (y-axis) are expressed as the sum of both early and
late stages of apoptosis (green bars); whereas cells stained only with PI and annexin V-FITC negative were counted as the
necrotic cell population (black bars). Calculations of two-tailed Student’s paired t-test of PND-treated cells as compared with
PBS-treated (*) and untreated (‡) cells controls, provided consistently values of P < 0.001, in both circumstances. Each bar
represents the mean of triplicates and error bars the standard deviation of the mean.

To discern if PND induces its cytotoxicity through apoptosis or necrosis, cells were
treated with two different concentrations of PND for 24 h, 34 μM and 68 μM for HL-60 and 11
μM and 22 μM for MDA-MB-231. Subsequently, cells were stained with annexin V-FITC and
PI and analyzed via flow cytometry. PND was found to induce significant PS externalization in
both cell lines as compared with positive and negative controls (P<0.001; Figure 3A and 3B).
PND induced significant PS externalization in HL-60 cells in a dose-dependent manner, showing
14.8% and 30.2% of apoptotic cells at 34 μM and 68 μM, respectively (P = 0.0033, Figure 3A).
Additionally, PND induced a higher percentage of PS externalization in MDA-MB-231 cells
than HL-60 cells at both concentrations tested with 67.2% and 71.1% positive annexin V cells at
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11 μM and 22 μM, respectively (Figure 3B). As expected, solvent treated and untreated cells did
not exhibit any significant increment in apoptotic or necrotic death (Figure 3A and 3B).
Furthermore, H2O2 induced its cytotoxic effect via apoptosis and necrosis on MDA-MB-231
and HL-60 cells, respectively (Figure 3A and 3B). Thus, PND caused PS externalization in both
MDA-MB-231 and HL-60 cells, which is a well-known early event in the activation of
apoptosis.
2.2.2 Assessment of Mitochondrial Involvement in Apoptosis Induced by PND
An early biochemical event triggering the intrinsic apoptosis pathway is mitochondrial
depolarization, which can be quantified by using a polychromatic JC-1 reagent and flow
cytometry26,27,28. JC-1 emits a red or green fluorescence signal when the mitochondria are
polarized or depolarized, respectively. MDA-MB-231 and HL-60 cells were seeded as described
in the previous section and treated with PND for 6 h. After treatment, the cells were harvested
and stained with 2 μM of the fluorophore 5,5’,6,6’-tetrachloro-1,1’,3,3’tetraethylbenzimidazolylcarbocyanine iodide (JC-1) following manufacturer’s instructions
(MitoProbe; Life Technologies, Grand Island, NY, USA). Cells with healthy polarized
mitochondria favor for JC-1 to form aggregates, which emit a red signal. Cells that have a
depolarized mitochondria exhibit a green signal, due to the dispersed JC-1 monomers. Similar
controls as above were concurrently analyzed. Data acquisition and analysis were achieved by
using CXP software (Beckman Coulter). Each data point was analyzed in triplicate.

11

A

B

Figure 4. PND induced phosphatidylserine externalization on HL-60 (A) and MDA-MB-231 (B) cancer cells after 24 h of
incubation. PND inflicted its cytotoxic effect via mitochondrial membrane depolarization on HL-60 (A) and MDA-MB-231 (B)
cells. Cells were treated with PND for 6 h, and changes in the mitochondrial membrane potential (ΔΨm) were monitored by
staining them with JC-1 and examined via flow cytometry. The JC-1 reagent emits a green fluorescence signal after
mitochondrial depolarization. (A-B) Percentages of cells emitting a green fluorescence signal, y-axis, versus different treatments,
x-axis, are depicted. 1 mM of H2O2 was used as a positive control as it strongly perturbs mitochondrial membrane potential
(ΔΨm). Each bar represents the mean of three replicates and error bar the standard deviation. Two-tailed Student’s paired t-test
of PND-treated cells, as compared with PBS-treated (*) and untreated (‡) cell controls, provided consistent values of P < 0.01 and
P < 0.001, respectively.

Consequently, both MDA-MB-231 and HL-60 cells were incubated for 6 h with PND and
the mitochondrial membrane potential (ΔΨm) status was recorded. As expected based on the PS
externalization data, both PND-treated cancer cells revealed significant mitochondrial
depolarization, as compared to untreated and solvent treated cells (Figure 4A and 4B). These
results indicate that PND is able to induce mitochondrial depolarization in both cancer cell types,
further indicating that PND induces cell death via the intrinsic apoptosis pathway.
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2.3 Identifying the Molecular Pathway of PND Induced Apoptosis
2.3.1 Cell Cycle Profile
To examine if PND can affect the proliferation/cell division of MDA-MB-231 and HL-60
cells, the cell cycle distribution profile was examined via flow cytometry (Figure 5). To
determine the effects of PND on cell cycle progression, a strategy to quantify cellular DNA
content that depends on a violet-excited DNA intercalating fluorophore, DAPI (4’,6-diamidino2-pheny- lindole) was utilized24,29. Asynchronous cultures in the exponential growth phase of
MDA-MB-231 and HL-60 cells in 24-well plates were treated with several doses of PND. After
72 h of incubation, cells were centrifuged and treated as in the previous section, fixed,
permeabilized and stained with DAPI; those three steps were accomplished by adding to the cells
200 μl of a single nuclear isolation medium (NIM)-DAPI solution (Beckman Coulter)29. The cell
suspension was then incubated for an additional 3 min at room temperature in the dark24. The
controls included in the series of experiments were as described for the previous experiments.
Approximately, 20,000 events (cells) were collected per sample using a flow cytometer equipped
with a solid-state 405 nm laser (Gallios; Beckman Coulter). The acquisition and distribution of
cell subpopulations within each of the cell cycle facets were accomplished by utilizing Kaluza
flow cytometry software (Beckman Coulter). Additionally, doublets were effectively eliminated
by including a single cell gate in the acquisition cell cycle protocol.
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Figure 5. PND affected the cell-cycle profile of two cancer cell lines, MDA-MB-231 (A-D) and HL-60 (E-H), and also
exhibited apoptosis-induced DNA fragmentation in a dose-dependent mode. After 72 h of PND treatment, cells were harvested,
fixed, permeabilized, stained with DAPI, and analyzed via flow cytometry. The percentages for each cell cycle phase are
presented along with the y-axis, whereas the different treatments are displayed along the x-axis. For this series of experiments,
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the following controls were involved: untreated cells and cells treated with 0.1% PBS solvent were used as negative controls,
while 1 mM of H2O2 was used as the positive control. Each bar denotes an average of three replicates, and the error bars indicate
their corresponding standard deviation. For assay data acquisition and analysis purposes, the FL 9 detector, a single-cell gate, and
Kaluza flow cytometry software (Beckman Coulter) were utilized.

After treatment of MDA-MB-231 cells with PND, a significant decrease of the G0/G1
cell subpopulation was observed; however, this effect was only observed at the highest
concentration of PND in HL-60 cells (Figure 5B and 5F). PND did not significantly affect or
decreased the S and G2/M subpopulations in both MDA-MB-231 and HL-60 cells as compared
with PBS and untreated controls (Figure 5B–5D and 5F–5H). Additionally, PND caused
significant DNA fragmentation in a concentration-dependent fashion in both cancer cell lines, as
denoted by a significant increase in the sub-G0/G1 subpopulation (P<0.0005; Figure 5A and 5E).
Differences in the percentages of both cells in each phase of the cell cycle between PBS-treated
and untreated cells were essentially indiscernible. Although the previous data were acquired
from unsynchronized cell populations, results obtained with synchronized MDA-MB-231 and
HL-60 cancer cell lines treated with PND (as in Figure 5) revealed few if any differences in the
way the cells reacted to PND (data not shown). As in Figure 5, PND elicited a dose-dependent
increase in DNA fragmentation, as shown by an increase in the sub-G0/G1 population in both
cell lines (data not shown). Essentially, the results were almost identical to those observed with
asynchronous populations of HL-60 and slightly depressed (lower) for MDA-MB-231. Cell cycle
analyses were also performed on the untransformed breast epithelial cell line, MCF-10A, at high
PND concentrations (matching the CC50 concentrations on MCF-10A; data not shown) and at
lower concentrations. A dose-dependent increase of sub-G1/G0 was detected at high PND
concentrations, reflecting an increase in DNA degradation, as expected from cells undergoing
cell death (data not shown). However, at low PND concentrations (matching CC50 values on
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MDA-MD-231 as used in Figure 5; data not shown), little if any changes in DNA fragmentation
were detected in the MCF-10A cell line. These experiments revealed that PND disrupted the
distribution of the cell cycle and induced DNA fragmentation (sub-G0/G1 population) in both
cancer cell types.
2.3.2 Interaction of PND with double stranded (ds) DNA
The potential interaction between PND and dsDNA was examined with the use of a DNA
mobility-shift assay using plasmid DNA as a binding substrate and compared to that of
quinacrine, a compound with comparable structure, and a well-known DNA intercalator. Each
reaction mixture was of 10 μl total volume in PBS pH 7.4. Both PND and quinacrine (SigmaAldrich) were tested at three individual concentrations of 1 μM, 0.5 μM or 0.25 μM,
respectively. To each reaction mixture, 100 ng of plasmid double-stranded (ds) DNA (pCMVdR8.91; Addgene, Cambridge, MA) was added and the mixture was then incubated for 30 min at
37 ̊C and stopped by adding 2 μl of 6X gel loading buffer and placed on ice. The potential
binding interaction between both PND and quinacrine with dsDNA were analyzed by using 1%
(w/v)-agarose-gel electrophoresis dissolved in TAE buffer (0.04 M Tris base, 0.04 M acetate and
0.001 M EDTA) pH 8.0. To stain the dsDNA complexes, Ethidium bromide was added to the
agarose gel throughout the electrophoresis process at a concentration of 0.5 μg/ml. DNA
migration was visualized by utilizing a gel documentation system, and pictures were captured by
using a UV- light trans-illuminator (Alpha Innotech, San Leandro, CA)30. The well-known DNA
intercalator fluorescent compound, Propidium iodide, was included as a positive control at 1 μg
per reaction, and untreated dsDNA was included to determine its normal electrophoretic mobility
in the gel.
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Figure 6 PND treatment resulted in DNA migration retardation in a dose-dependent manner. Three different concentrations of
PND and quinacrine were incubated individually with 100 ng of plasmid DNA and the potential of complex formation was
analyzed via agarose gel electrophoresis. Reaction products were separated by 1% agarose gel electrophoresis in
Tris/acetate/EDTA buffer and stained with Ethidium bromide. Both PI and free plasmid DNA were used as positive and negative
controls of DNA mobility, respectively. The loading wells are located on the top of the image indicated by two blue head arrows
(top left and right corners). The yellow dashed line is indicating the maximum mobility of the free supercoiled DNA is included
as a reference. Three DNA mobility-shifts are indicated by blue lines and arrows (left side of the image). The migration direction
of DNA is indicated by an arrow (right side of the image); from the cathode (negative) to the anode (positive). A representative
image used to review the potential formation of DNA complexes is depicted.

Typically, an experimental compound intercalating or binding to double-stranded (ds)
DNA will increase the molecular mass after forming complexes that decrease its electrophoretic
mobility in an agarose gel, as compared with untreated DNA. When 1 mM of PND was
incubated with DNA a marked reduction of migration of PND-treated DNA was observed, as
compared with free plasmid DNA (shifts are indicated to the left side of Figure 6).
Approximately half of the total input DNA was located in the loading well with minimum
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mobility into the agarose gel. Furthermore, when 0.5 and 0.25 mM of PND were incubated with
DNA, there was a clear reduction in mobility (noted to the left side of Figure 6). Additionally,
PND-treatment did not result in DNA degradation based on the absence of DNA fragments
smaller than the free supercoiled DNA (Figure 6)30. In previous studies, quinacrine, with a
similar chemical structure to PND, was also found to interact with DNA by intercalation31,32. As
shown in Figure 6, quinacrine caused the maximum retardation of DNA mobility at the highest
concentration tested (1 mM) as evidenced by a smear indicative of complexes with supercoiled
DNA. Also, quinacrine provoked a evident retardation of the DNA mobility, similar to PND,
when tested at 0.5 and 0.25 mM (Figure 6). As was the case with DNA treated with PND,
quinacrine did not exhibit any DNA degradation activity (Figure 6). As expected, PI, which was
used as a positive control for DNA binding, also provoked retardation of DNA mobility. Our
results indicate that PND can interact directly with DNA provoking its mobility shift in agarose
gels. Similar behavior to that of quinacrine might suggest that PND can also intercalate between
dsDNA bases.
2.3.3 UV-Visible spectrophotometric titration
Pyronaridine is an acridine derivative. It has been shown that acridines upon binding to DNA
undergo hypochromic shifts in their visible absorption spectra. To further prove the intercalative
interaction of PND with calf-thymus (CT) dsDNA, spectrophotometric titrations were performed
in Tris/HCl buffer. UV-Visible measurements were taken in a Varian Cary 100
spectrophotometer. Calf Thymus (CT) DNA and buffers were purchased from Sigma Aldrich.
The binding constant of PND with CT DNA was determined by absorption titration at room
temperature through stepwise addition of a CT DNA solution (10.1 mM; 5 μL additions) in
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buffer (5 mM Tris/HCl, 50 mM NaCl, pH = 7.39) over a 2 mL working solution of PND (22.8
μM) in the same buffer. Absorption spectra were recorded at 424 nm, and the titration was
terminated when saturation was reached. In order to determine the binding affinity, the data were
fitted to the Scatchard equation r/Cf = K(n-r) (McGhee and von Hippel plots)33,34, where r is the
number of moles of PND bound to 1 mol of CT DNA, n is the number of equivalent binding
sites, and K is the affinity of the complex for those binding sites. Concentrations of free (Cf) and
bound (Cb) complexes were calculated from Cf = C(1−α) and Cb = C−Cf, respectively, where C
is the total PND concentration. The fraction of the bound complex (α) was calculated from α =
(Af−A)/ (Af−Ab), where Af and Ab are the absorbances of the free and fully bound drug at the
selected wavelengths, and A is the absorbance at any given point during the titration. The plot of
r/Cf vs. r gives the binding constant Kb as the slope of the graph35. All experiments were
performed in triplicate, and values of Kb were averaged.
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Figure 7. Calf Thymus DNA caused a hypochromic and bathochromic effect on PND maxima of absorbance. (A) UV-Visible
spectrophotometric titration (300–650 nm) of PND (22.8 μM) in Tris/HCl buffer upon consecutive additions (a-j) of Calf Thymus
(CT) DNA (10.1 mM) . The arrow indicates the spectral changes when DNA is added. (B) Summary of the UV-Visible titration
data from PND and CT DNA interaction.

PND displays strong absorption bands in the 300–500 nm region typical for transitions
between conjugated aromatic rings' electron energy levels. In general, hypochromic and
bathochromic effects observed on maxima of UV-Visible absorbance can be taken as evidence of
stacking interactions between conjugated aromatic systems that intercalate the nucleobases of
DNA. Figure 7A shows the absorption spectra of PND in the studied region upon consecutive
additions of CT DNA. The black line represents the spectra of PND at 22.8 uM, while the
colored lines represent the spectra of PND when 10.1 uM of CT DNA is added sequentially. The
intensity of the absorption band diminishes as a consequence of DNA intercalation. The
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maximum absorbance at 424 nm was studied to diagnose the compound-DNA interaction. Our
results show a significant hypochromic effect (39%) and a red-shift of 8 nm. In addition, the
Scatchard equation33,34 was used to determine the binding affinity [8.5 ± 0.7 x 105 M-1] of PND
to CT DNA. All binding data of PND with CT DNA, shown in Figure 7B, are comparable to that
of well-known intercalating agents with similar structure36,37. They indicate that PND is also able
to intercalate between the DNA bases, as suggested by the mobility-shift assay.
2.3.4 Circular Dichroism Spectroscopy
In addition, detailed DNA conformational alterations were studied by means of circular
dichroism spectroscopy in Tris/HCl buffer. Circular dichroism (CD) spectroscopy measures the
differential absorption of left and right circularly polarized light. Conformational changes in the
structure of macromolecules can be assessed using this method. Circular dichroism spectra
measurements were taken in a JASCO-1100 spectropolarimeter equipped with a Xenon lamp
(JASCO, Easton, MD). A CT DNA stock solution was prepared in Tris/HCl buffer (5 mM
Tris/HCl, 50 mM NaCl, pH = 7.39) and its concentration (4.325 mM) was
spectrophotometrically determined using molar extinction coefficient 6600 M-1cm-1 at 260 nm.
A 150 μM dilution in Tris/HCl buffer was prepared and used for the experiments35. A 2.0 mM
stock solution of PND was freshly prepared in MQ water prior to use. The appropriate volume of
this solution was added to 3 ml working solutions of 150 μM CT DNA to achieve molar ratios of
0.03, 0.06, 0.2, and 0.3 PND/DNA. Samples were prepared in triplicate and incubated for 30
minutes and 20 hours. All CD spectra of DNA and DNA/ PND were recorded at 25 ̊C over the
range 205–380 nm, and finally corrected with a blank and noise reduction. The final data is the
average of three experiments, and it is expressed in millidegrees (mdegs).
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Figure 8. PND induced an increase in the intensity of the positive and negative bands of the circular dichroism spectra of
Calf Thymus DNA. Changes in the circular dichroism (CD) spectra of Calf Thymus (CT) DNA as it interacts with PND. CT
DNA (150 μM) in Tris/HCl buffer was subjected to CD analysis after 30 min (A) or 20 h (B) of incubation with PND at molar
ratios of 0.03, 0.06, 0.2, and 0.3. The arrows specify the CD spectral changes of CT DNA under a gradient of increasing PND
concentrations. Blanks of CD spectra with the same gradient of PND concentrations in the absence of CT DNA incubated for 20
h (C). Millidegrees = mdegs.

A typical CD spectrum of CT DNA in its B form shows a positive band with a maximum
at 275 nm due to base stacking and a negative band with a minimum at 248 nm due to righthanded helicity38. Therefore, changes in the CD signals can be assigned to corresponding
changes in DNA secondary structure. Figure 8A and 8B shows the CD spectrum of CT DNA,
and the effect of treating it with increasing amounts of PND for 30 minutes and 20 hours,
respectively. Our results show that PND was able to increase the intensity of both the negative
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and the positive bands in a concentration dependent manner but with no significant red-shifts in
any of them. These results are comparable to previously reported similar compounds and
suggested that PND is able to stabilize the right-handed B form of DNA with no significant
conformational changes37,39. The fact that the same spectral changes were observed upon 30
minutes and 20-hour incubations suggests that the kind of interaction taking place occurs in a
few minutes, confirming the intercalative binding mode. Besides, a positive signal appeared in
the range 300–360 nm, a region where DNA does not absorb light. This suggests that some
asymmetrical change is possibly being induced on PND upon binding to CT DNA40, since no
detectable CD activity for PND or CT DNA alone was observed between the 300-360 nm.
Interestingly, a study in which the binding of ethidium bromide to DNA components is
investigated, shows CD activity in the 300-360 nm region41. It is concluded that the induced CD
band originates mostly from ethidium bromide binding to the adjacent base pairs of a double
helical nucleic acid41. With this information we can hypothesize that PND may also be binding to
adjacent base pairs in the CT DNA thus showing CD activity at the 300-360 nm range.
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Chapter 3: Pre-Clinical Invitro Combination And In-Vivo Studies
In the previous chapter, we reported that PND shows potential as a well-tolerated
anticancer drug. In this chapter, we elucidate one of the mechanisms by which PND induces cell
death. Pyronaridine has been shown to exert cytotoxic activity on 17 different cancer cell lines,
and induced cell death via apoptosis. To further investigate the anticancer potential of PND, we
sought to determine its mode of action in cancer cells, more specifically on breast cancer cells.
Our previous study demonstrated PND to be more cytotoxic and selective in most breast cancer
cell lines42. Breast cancer is the most common cancer in women worldwide, and approximately 1
in 8 women will be diagnosed with invasive breast cancer in their lifetime43,44. Currently, local
and systemic treatment options are available to treat this type of cancer. These include surgery,
radiation, neoadjuvant therapy, endocrine therapy, anti-HER2 targeting, and chemotherapy45.
While there are multiple therapies available to treat the variety of breast cancer subtypes, there is
a possibility of reoccurrence and drug resistance43,46,47,48. Thus, investigating PND’s mode of
action in breast cancer cells was deemed of high importance.
Prior studies had revealed that PND acts as a topoisomerase II inhibitor in Plasmodium
falciparum11. We previously demonstrated that PND intercalates with DNA, and in this chapter,
we seek to confirm that PND is a bona fide topoisomerase II inhibitor in mammalian cells.
Through transcriptome analysis performed on the MDA-MB-231 breast cancer cell line, we were
able to determine that PND induces gene signatures that correlate with those of known
topoisomerase II inhibitors. Furthermore, we demonstrate that PND inhibits topoisomerase II in a
dose-dependent manner by using the decatenation-supercoiling assay. In addition, we report the
first study in which PND is used to reduce tumor size in mice with human breast cancer
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xenografts. Additionally, we show combinational studies of PND with well-known anticancer
drugs to elucidate their cytotoxic potential. Overall, the data strongly suggest that PND is a
strong candidate for anticancer therapy.
3.1 Identifying the Molecular Target of PND
3.1.1 Transcriptome Analysis
To identify PND’s molecular target, a transcriptome analysis was performed.
Transcriptomic analyses capture a snapshot at a given time of the total number of transcript
copies existing in cells49. For this purpose, the MDA-MB-231 cells were seeded in 6 well plates
at 1,000,000 cells/1mL. After seeding, cells were exposed to 11 µM PND and incubated for 6 h.
Additionally, transcripts from cells incubated with PBS, as solvent control, were also examined
and used as a reference for the analysis. After incubation, the cells were harvested, washed,
centrifuged, and the supernatant was discarded. The cell pellets were stored at -80°C. Three
independent biological replicates were executed for each treatment. The total RNA extraction
was performed the next day by using the RNeasy Mini Kit (Qiagen;74,104). After RNA
extraction, samples were incubated with 10 µL of DNase I for 15 min at room temperature. The
RNA was quantified using Qubit Fluorometer (Thermo Fisher; Q33216), and its integrity was
examined using TapeStation 2200 (Agilent Technologies, Santa Clara, CA). The Truseq
Stranded mRNA kit was implemented to produce pair-ended libraries, and the RINe from the
TapeStation was used to ensure high-quality samples. The transcriptome samples were loaded
into the NextSeq 500 system for sequencing (Illumina, San Diego, CA).
3.1.2 Connectivity Map Analysis
The CMap database contains a large collection of genome-wide transcriptional
expression data of drug-treated cancer cells and allows for comparisons of data across
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experimental platforms of common gene-expression changes50,51,52. The transcriptomics
perturbation molecular signatures induced by PND on MDA-MB-231 cells were used as inputs
to query CMap using itsclue.io tool (https://clue.io)50, in order to obtain similarity scores for the
signatures associated to the small molecule perturbagens available at CMap.

Expression signatures of PND-treated cells obtained through a transcriptome analysis
were compared to the expression signatures of drug-treated cells. The connectivity map (CMap)
is a collection of genome-wide transcriptional expression data and allows for comparisons of
data across experimental platforms of common gene-expression changes49,50. The data from the
CMAP comparison revealed that PND gene expression pattern in MDA-MB-231 cells is very
similar to the gene expression profile of drugs that inhibit topoisomerase II, such as pidorubicine,
doxorubicin, and pirarubicin on other cancer cells (Table 2).
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Table 2.. Comparison of PND-treated MDA-MB-231 cells to gene expression profiles in CMAP

PC3
VCAP
A375
A549
HA1E
HCC515
HT29
MCF7
HEPG2
Summary

Cell lines

#

Median
score

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43

99.58
99.56
99.56
99.49
99.49
99.46
99.46
99.45
99.44
99.44
99.40
99.35
99.31
99.22
99.11
98.96
98.93
98.89
98.82
98.77
98.76
98.73
98.73
98.73
98.68
98.68
98.64
98.63
98.59
98.56
98.53
98.39
98.28
98.00
97.99
97.94
97.83
97.83
97.77
97.64
97.61
97.30
97.14

Type

Name

Description

BRD-K77681376
triptolide
pidorubicine
ER-27319
PIK-75
doxorubicin
pirarubicin
AT-7519
daunorubicin

casein kinase inhibitor, FLT3 inhibitor
RNA polymerase inhibitor
topoisomerase inhibitor ,DNA intercalating drug
mediator release inhibitor, syk inhibitor
DNA protein kinase inhibitor, P110 inhibitor
topoisomerase inhibitor, DNA intercalating drug
topoisomerase inhibitor
CDK inhibitor, cell cycle inhibitor

ZG-10
bisindolylmalelmide-ix
alvocidib
PF-56227
BMS-345541
Topoisomerase inhibitor
dactinomycin
BRD-K53780220
JNJ-7706621
dactinomycin
BRD-K53780220
chromomycin-a3
THM-I-94
topotecan
BI-2536
piperlongumine
mitoxantrone
daunorubicin
doxorubicin
TG-10134B
vorinostat
trichostatin-a
trichostatin-a
dorsomorphin
CGP-60474
topotecan
HDAC inhibitor
daunorubicin
5-iodotubercidin
camptothecin

RNA synthesis inhibitor, topoisomerase inhibitor
JNK inhibitor
PKC inhibitor, glycogen synthase kinase inhibitor
CDK inhibitor, apoptosis stimulant, BCL inhibitor
focal adhesion kinase inhibitor
IKK inhibitor
DNA directed RNA polymerase inhibitor
radical formation stimulant
CDK inhibitor, Aurora kinase inhibitor
DNA directed RNA polymerase inhibitor
casein kinase inhibitor, FLT3 inhibitor
DNA binding
HDAC inhibitor, apoptosis stimulant
topoisomerase inhibitor
PLK inhibitor, apoptosis stimulant
glutathione transferase inhibitor
topoisomerase inhibitor, DNA intercalating drug
RNA synthesis inhibitor, topoisomerase inhibitor
topoisomerase inhibitor, DNA intercalating drug
JAK inhibitor, FLT3 inhibitor, RET tyrosine kinase
HDAC inhibitor , cell cycle inhibitor
HDAC inhibitor, CDK expression enhancer
HDAC inhibitor, CDK expression enhancer
AMPK inhibitor, DNA damaging
CDK inhibitor, PKC inhibitor
topoisomerase inhibitor
RNA synthesis inhibitor, topoisomerase inhibitor
adenosine kinase inhibitor

topoisomerase inhibitor
AS-601245
JNK inhibitor
idarubicin
topoisomerase inhibitor
Bromodomain inhibitor
Bellinostat
HDAC inhibitor, cell cycle inhibitor
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3.2 Confirming Molecular Target of PND
3.2.1 Topoisomerase II Inhibition
The PND topoisomerase inhibitory effect was determined by the decatenation of a
kinetoplast (k)DNA53. The assay was performed according to the manufacturer’s instructions
(TopoGEN, Buena Vista, CA, USA). A typical reaction mixture of 20 µl volume includes the
following reactants: 0.5 M Tris- HCl (pH8), 1.50 M NaCl, 100 mM MgCl2, 5 mM dithiothreitol,
300 µg BSA/ml, and 20 mM ATP in water. Samples were pre-incubated at 37°C for 30 minutes
prior to the addition of the topoisomerase II enzyme. Subsequently, the reaction was initiated by
the addition of the topoisomerase II (diluted 1:2) and incubated for 30 min at 37°C. The
reactions were stopped using 5x stop buffer (5% Sarkosyl, 0.125% bromophenol blue, 25%
glycerol). Next, samples were analyzed by using 1% (w/v)-agarose-gel electrophoresis dissolved
in TAE buffer (0.04 M Tris base, 0.04 M acetate and 0.001 M EDTA) pH 8.0. Afterward, gels
were stained with Ethidium Bromide (EtBr; 0.5 µg/ml) and imaged through the Gel Doc XR+
imaging system (Bio-Rad, Hercules, CA, USA). The digital images were used to analyze the
migration patterns.
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Figure 9. PND caused inhibition of topoisomerase II activity in a dose-dependent manner. The gel loading lanes are numbered
on top of the gel and indicate the following: (1) catenated kinetoplast DNA (kDNA); (2) decatenated kDNA; (3) linear kDNA; (4)
kDNA plus topoisomerase II; (5) kDNA plus topoisomerase plus 5 µM of PND; (6) kDNA plus topoisomerase plus 50 µM of PND;
(7) kDNA plus topoisomerase plus 500 µM of PND; (8) kDNA plus topoisomerase II plus 1 mM etoposide; (9) kDNA plus
topoisomerase II plus PBS; (10) kDNA plus topoisomerase II plus DMSO.

To test the ability of PND to inhibit topoisomerase II, the decatenation of kinetoplast
DNA (kDNA) was analyzed by using an agarose gel electrophoresis approach53. The
preincubation of increasing concentrations of PND (5, 50, 500 µM) with the topoisomerase II
enzyme, followed by the addition of kDNA, showed a dose-dependent inhibition of decatenation
with complete inhibition of topoisomerase activity resulting in no decatenation at 500 µM of
PND (Figure 9; lanes 5-7). Etoposide, a well-known topoisomerase II inhibitor, included as a
positive control, showed a partial enzyme inhibition with an incomplete decatenation at 1mM
(Figure 9; lane 8) as opposed to the negative control included (enzyme + kDNA; figure 9, lane 4)
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were a complete kDNA decatenation was observed. Our results demonstrate that PND acts as a
bona-fide topoisomerase II inhibitor
3.3 Evaluating PND in-vivo
3.3.1 PND Pilot experiment using subcutaneous model
To evaluate whether PND’s activity translates to a reduction of tumor growth in-vivo, we
tested PND on mice subcutaneously implanted with MDA-MB-231 LM2-4 tumor cells. C.B17/IcrHan®Hsd-Prkdc severe combined immunodeficiency (SCID) female mice were purchased
from Envigo (Indianapolis, IN). After a two-week acclimation period, we performed
subcutaneous implantation of tumor cells to the right flank of the mice. Prior to injection, MDAMB-231 LM2-4 cells were harvested with 0.25% trypsin, washed with PBS, and resuspended in
DMEM. A total of 2.5 million cells /200 µl per mouse were implanted. PND was administered
orally via gavage. This was due based on an acute toxicity test in which we observed intestine
inflammation when PND was administered via intraperitoneal injection. The mice were
monitored daily, observing for variations in body weight and tumor growth. Vernier calipers
measured tumor volume and calculated using the formula (length x width2)/2. Experimental
endpoints were determined based on institutional guidelines. Results were plotted as event-free
survival (Kaplan-Meier analysis) over time. Mice with the primary tumor size progression
beyond 1200 mm3 or ≥15% weight loss were euthanized as previously described54.

Oral administration of PND at 160 mg/kg/day (n=3) inhibited tumor growth (P<0.0001
PND vs. control), as shown in Figure 10A. Control mice with xenografted tumors and not treated
with PND (n=5) did not prevent tumor growth, which proliferated rapidly as compared to PNDtreated mice. To assess whether PND exerts any adverse and/or nonspecific toxic side effects in30

vivo, the bodyweight of PND-treated and untreated control mice were monitored concomitantly
throughout the course of the experiment, as previously described54. Even though there was a
significant difference between weights of control and treated mice P=0.0167, the weight
remained constant within each group since the beginning of the study (data not shown). In
addition, we used the Kaplan-Meier plot to show tumor responses, as shown in Figure 10B. The
time to 50% event-free survival of the PND treatment was 29 days compared to the control
group, which was 23 days. Moreover, there was a significant impact on survival with a P-value
of 0.041.

B

A

Figure 10. Effect of PND treatment on the growth of MDA-MB-231 LM2-4 tumors.(A) Human MDA-MB-231 LM2-4 cells were
implanted subcutaneously in SCID mice. Therapy began when tumors reached approximately 260 mm3; the control mice (n=5)
received MiliQ water (gavage) or PND (n=3) P<0.0001 PND vs. control (mean values ± s.d.) (B) Event-free survival analysis
(Kaplan-Meier analysis), significant event-free survival was observed with PND P<0.05
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3.4 PND in Combination with Known Anticancer Drugs
It has been previously discussed that the combination of two or more drugs that have
different mechanisms of action is an alternative approach to increase the success of a drug to be
repurposed55. In the present study, we used PND combined with Cisplatin, Gemcitabine, MG132,
Melphalan, Bortezomib, Doxorubicin, and two novel drugs, 2350 and P2 (Figure 11).

Gemcitabine

Cisplatin

MG-132

Bortezomib

P2
Melphalan

Doxorubicin
2350

Figure 11. The chemical structures of Cisplatin, Gemcitabine, MG132, Melphalan, Bortezomib, Doxorubicin, 2350, and P2.

To examine the PND cytotoxic effect in combination with well-known anticancer drugs,
the Differential Nuclear Staining (DNS) assay was utilized20. Cells were seeded at a density of
10,000 cells/well in 96-well plates and incubated overnight. Cells were then treated with a
concentration gradient as follows, cisplatin (95.4 µM, 47.7 µM, 23.8 µM, 11.92 µM, 5.96 µM),
gemcitabine (0.44 µM, 0.22 µM, 0.11 µM, 0.05 µM, 0.02 µM), MG132 (0.5 µM, 0.25 µM,
0.125 µM, 0.06 µM, 0.03 µM), Melphalan (187 µM, 93.5 µM, 46.75 µM, 23.37 µM, 11.68 µM),
Bortezomib (0.01 µM, 0.005 µM, 0.0025 µM, 0.00125 µM, 0.00062 µM), Doxorubicin (1.2 µM,
0.6 µM, 0.3 µM, 0.15 µM 0.075 µM), 2350 (2 µM, 1 µM, 0.5 µM, 0.25 µM, 0.125 µM) and P2
(3.8 µM, 1.9 µM, 0.95 µM, 0.475 µM, 0.2375 µM). The cells were then incubated for 24 h.
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Next, 5.5 µM of PND, its CC50 at 24 h, was administered to drug-treated wells, and an additional
incubation of 24 h was implemented. The CC50 stands for the cytotoxic concentration of
compound that results in 50 % cell death. Approximately 2 hours before imaging, a mix of
Hoechst 33342 and Propidium iodide (PI; Invitrogen) were added to each well at a final
concentration of 5 µg/ml each fluorophore. Image acquisition and data analyses, including image
segmentation, were performed using the IN Cell Investigator software, specifically designed to
assist the IN Cell 2000 bioimager system (GE Healthcare Life Sciences, Pittsburgh, PA). In the
study, the following controls were utilized: PBS as solvent/vehicle control, 5.5 µM PND to
assess the individual PND cytotoxicity on these cell lines, and hydrogen peroxide (H2O2) as a
control for cytotoxicity. For each treatment, three biological replicates were performed.
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in combination with a concentration gradient of gemcitabine (A),

cisplatin (B) MG-132 (C), and bortezomib (D) on MDA-MB-231 cells. (A) MDA-MB-231 cells were pre-incubated with a
concentration gradient of gemcitabine (CC50, ½ CC50, ¼ CC50, 1⁄8 CC50, 1⁄16 CC50) for 24 h, followed by a dose of 5.5 µM of PND and incubated
for an additional 24 h. (B) MDA-MB-231 cells were pre-incubated with a concentration gradient of cisplatin (CC50, ½ CC50, ¼ CC50, 1⁄8 CC50, 1⁄16
CC50) for 24 h, followed by a dose of 5.5 µM of PND and incubated for an additional 24 h. C) MDA-MB-231 cells were pre-incubated with a
concentration gradient of MG-132 (CC50, ½ CC50, ¼ CC50, 1⁄8 CC50, 1⁄16 CC50) for 24 h, followed by a dose of 5.5 µM of PND and incubated for an
additional 24 h. D) MDA-MB-231 cells were pre-incubated with a concentration gradient of bortezomib (CC50, ½ CC50, ¼ CC50, 1⁄8 CC50, 1⁄16
CC50) for 24 h, followed by a dose of 5.5 µM of PND and incubated for an additional 24 h. The following controls were included: PBS as solvent
control; PND CC50 24 h (5.5 µM); and 1 mM of H2O2 as a positive control for cytotoxicity incubated for 48 h. A P-value of ≤ 0.05 was
considered significant. Two-tailed Student’s paired t-test of combination-treated cells, as compared with single drug-treated (*) and PND-treated
(‡) cells, provided consistent deemed significant P (≤ 0.05) values respectively.

Four clinical drugs, particularly, gemcitabine, cisplatin, MG132, and bortezomib, were
shown to have a higher cytotoxic effect when PND was added concomitantly (Figure 12). A
single concentration of PND was tested in combination with a concentration gradient of
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H2O2
H202

gemcitabine, cisplatin, MG-132, or bortezomib. As shown in Figure 12A, the PND and
gemcitabine combination shows a significant increase in cytotoxicity compared with gemcitabine
(P= 5.92 E -07), or PND (P= 2.7 E -05) alone. A similar effect was observed when cisplatin,
MG132, and bortezomib were tested, in combination with PND (Figure 12 B-D). Thus, it can be
concluded from these results that the combination of PND with these well-known drugs produces
higher cytotoxicity as compared to single-drug treatment. Therefore, our results demonstrate a
synergistic effect of PND with each drug, resulting in more significant cell toxicity as compared
to single-drug treatment. We were able to observe that while keeping a constant concentration of
PND and reducing the doses of the other drugs, there was a higher cytotoxic effect in breast
cancer cells.
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Chapter 4: PND And Drug Resistance
As stated in the introduction, patients who suffer from cancer reoccurrence do so in part
because of drug resistance. It has been observed that even the most successful and impactful
anticancer drugs have acquired mechanisms of resistance56. In order to assess and possibly
overcome such resistance happening with PND, we first had to evaluate if PND treatment would
cause resistance in cancer cells. This chapter investigates PND’s potential to cause drug
resistance in a breast cancer cell line (MDA-MB-231). In addition, we evaluate PND as an
alternative therapy option for a Paclitaxel resistant cell line.
4.1 Identifying Drug Resistance
4.1.1 Generation of resistant cell lines
MDA-MB-231 cells were used to generate PND- resistant cell lines. MDA-MB-231
resistant variants (MDA-MB-231-P1, MDA-MB-231-P2, MDA-MB-231-P3, MDA-MB-231-P4)
were treated daily with PND 0.69 µM for 6 weeks followed by a gradual increase to 1.38 µM for
6 more weeks (Figure 13).
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Figure 13. A conducted flowchart strategy and methodology utilized in this study to generate a PND-resistant cell line is
depicted.

It was hypothesized that with a slow selective continual pressure, the cells would become
resistant. It was observed that PND-resistant cell lines grew more slowly than parental cells. We
also initially perceived what seemed like a slight change in morphology between parental and
resistant cell lines (Figure 14). The cell variants seemed to be more elongated, and this is a trait
that has been previous observed in drug-resistant cell lines57,58. Upon closer inspection using
confocal imaging, a slight difference in morphology was observed (Figure 14). The growth rate
of the variants fluctuated throughout the dosing period. While some cells-maintained viability,
after continuous dosing, growth was severely affected. A rescue period of approximately 1 week,
with no PND treatment, was implemented to allow for cell regrowth without the toxic
aggression.
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Figure 14. Morphological comparison of MDA-MB-231 PND resistant variants.(A) Bright-field microscopic images of MDAMB-231-P1, MDA-MB-231-P2 , MDA-MB-231-P3, MDA-MB-231-P4 and MDA-MB-231 respectively. (B) Confocal
microscopic images of MDA-MB-231-P1, MDA-MB-231-P2, MDA-MB-231-P3, MDA-MB-231-P4 and MDA-MB-231
respectively.

4.1.2 Assessing drug resistance
To confirm PND resistance, the DNS assay was performed20. MDA-MB-231 variant P1
cells were seeded at 10,000 cells/well density in a 96-well plate in 100 μl of culture media,
incubated overnight, and treated with a gradient of PND concentrations for 24 h. The CC50 value
of MDA-MB-231-P1 was 6.17 µM ± 0.4. To determine the acquired degree of resistance in the
cell variant, the resistant index (RI) was calculated as previously mentioned59. The following
equation was used to calculate the RI, R= CC50 resistant cell line/ CC50 sensitive cell line. Upon
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comparing the CC50 values, resistance index, and P-value of the resistant and parental cell line,
PND is not causing resistance in the cell variant (Table 3). While the CC50 is approximately 2x
higher in the resistant variant, it is not deemed sufficient to catalog the variant as resistant as it is
only 0.65-fold resistant to PND.
Table 3. PND cytotoxic concentration 50% (CC50) and resistance index (RI) on MDA-MB-231 PND resistant cell line (MDAMB-231-P1) and parental MDA-MB-231 cell line. A P-value of ≤ 0.05 was considered significant. Two-tailed Student’s paired
t-test of MDA-MB-231-P1 cells, as compared with MDA-MB-231 cells, provided consistent significant P (≤ 0.05) value.

Cell Line

CC50 (µM )

Resistance

P-Value

Index
MDA-MB-231-P1

6.17 ± 0.42

0.65
0.01

MDA-MB-231

3.99 ± 0.06

-

4.2 Investigating PND cytotoxicity in resistant cell lines
PND's cytotoxicity was tested on an MDA-MB-231 Paclitaxel (PTX-231) resistant cell
line to further explore PND's activity in drug-resistant cell lines. The PTX-231 cell line was
obtained from a lab collaborator who will soon publish a paper on this resistant cell line. Using
the DNS assay20, cells were seeded at 10,000 cells/well density in a 96-well plate in 100 μl of
culture media, incubated overnight, and treated with a concentration gradient of PND for 24 h.
The CC50 value at 24 hours for the PTX-231 cell line was 5.7 µM (Figure15, Table 4). When
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comparing the CC50 of this resistant cell line to the CC50 of the parental cell line (3.9 µM), we
can conclude that PND causes cytotoxicity and is still highly selective to the resistant cell line.

100

MDA-MB-231 PTX
Resistant

90

% cell death

80
70
60

CC50

50
40
30
20
10
0
1

10 µM
PND

2
5 µM
PND

2.53µM
PND

1.254µM
PND

5
PBS

H26O2

Figure 15. Representative PND dose-response curve utilized to determine the CC50 values. For this analysis, cells were
exposed for 24 h to PND, and cell viability was determined via the DNS assay. MDA-MB-231 Paclitaxel resistant cells were
treated with a PND concentration gradient, as indicated on the x-axis, while the percentage of cytotoxicity (dead cells) is shown
on the y-axis. In this series of experiments, several controls were included: untreated cells and cells treated with the PBS diluent
alone (0.5% v/v) were used as negative controls, while 1 mM H2O2 was used as a positive control of cytotoxicity. Each
experimental point represents the mean of three replicas and error bars their corresponding standard deviation.
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Table 4. PND cytotoxic concentration 50% (CC50) and selective cytotoxicity index (SCI) on MDA-MB-231 Paclitaxel resistant
cell line (PTX-231) and parental MDA-MB-231 cell line. The non-cancerous cell line MCF-10A cell line was used to determine
the SCI.

Cell Line

CC50 (µM )

St Dev

SCI

PTX-231

5.7

0.5

6.05

MDA-MB-231

3.9

0.06

8.84
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Conclusion
5.1.1 Discussion
In all the cancer cell lines analyzed, PND treatment was found to cause cell death at low
micromolar concentrations (from 1.6 μM to 9.4 μM). Apart from being less toxic for noncancerous cells (MCF-10A; CC50 of 6.6 μM), PND displayed favorable selectivity on breast,
ovarian, and melanoma cancer cell lines, as compared with non-cancerous cells, with an SCI
value greater than 2.5 (see Table 1). PND also exhibited favorable SCI values (from 1.43 to 3.47)
on leukemia/lymphoma cells showing the highest selectivity on HL-60 cancer cells.
The mode of action of PND was analyzed in both the MDA-MB-231 and HL-60 cancer
cell lines. After exposure to a toxic agent, cells can undergo two main cell death routes,
apoptosis or necrosis21. Phosphatidylserine (PS) is preferentially located on the plasma
membrane leaflet's inner side, facing the cytosol. When cells initiate the apoptosis pathway, PS is
translocated to the plasma membrane's outer leaflet, a biochemical hallmark of apoptosis. Flow
cytometry identified this apoptotic facet when using PI and FITC-conjugated annexin V, which
has a high affinity for PS24,25. PND-treated MDA-MB-231 and HL-60 cells consistently exhibited
PS externalization, suggesting that PND uses the apoptosis pathway to inflict its cytotoxicity in a
dose-dependent manner.
Furthermore, apoptosis can be initiated via intrinsic or extrinsic biochemical pathways60.
A critical biochemical event triggering the activation of the intrinsic pathway is through
mitochondrial depolarization61. Therefore, MDA-MB-231 and HL-60 cells were exposed to PND
and stained with the polychromatic JC-1 reagent to investigate whether the mitochondrial
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depolarization was involved in its mechanism to induce cell death. Our data clearly indicate that
both cancer cell lines exhibited a significant mitochondrial depolarization after exposure to PND,
indicating that the intrinsic apoptosis pathway is induced.
The retardation of DNA migration can readily detect the interaction between DNA and
drugs or proteins during the mobility-shift assay via gel electrophoresis62. In these DNA binding
assays, the experimental compound-DNA complexes migrate more slowly than the free DNA
(uncomplexed DNA control), which results in DNA having a heavier molecular weight.
Additionally, when incubating a chemical compound with plasmid DNA, it is possible to detect
any harmful effects resulting in DNA degradation or fragmentation63. Our results indicate that
PND interacts directly with DNA since it causes significant DNA retardation in agarose gels, in a
concentration-depended manner but did not cause DNA degradation30. Quinacrine was included
in this series of experiments since it intercalates with dsDNA64, and it exhibited a similar DNA
retardation pattern as PND. Both PND and Quinacrine have a similar acridine backbone that
provides a planar structure to both PND and quinacrine molecules, allowing them to intercalate
by stacking into the base pairs of DNA64. The intercalative mode of DNA binding of PND was
confirmed by UV-Visible spectrophotometric titrations as well as circular dichroism of CT
DNA. Results from these DNA binding assays are comparable to those obtained with other DNA
intercalating drugs37,39,40 as well with some acridine derivatives that have shown DNA binding
properties65 and, therefore, we hypothesize an analogous mode of interaction. In addition, CD
spectra provided evidence of CT DNA stabilization in its B form with no detectable
conformational changes upon interaction with PND. Collectively, the mobility-shift assay, UVVisible, and CD series of experiments provide compelling evidence that PND binds DNA by
intercalating with nucleobases of the DNA.
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In addition, we aimed to investigate PND’s mode of action on cancer cells by conducting
a whole transcriptome analysis. These analyses were used to compare the PND-induced
expression signatures to other known drugs available on the CMap database. The CMap database
encompasses gene profiles of human cancer cell lines exposed to chemicals and other
perturbagens41. More specifically, the CMap database contains the gene expression profiles of
nine cancer-derived human cell lines exposed to 27,927 perturbagens50,51. These comparisons
revealed that PND affects the expression of genes that are similar to the gene signatures of
topoisomerase II inhibitors. To further confirm that PND is a topoisomerase II inhibitor, a
biochemical assay was performed. The results demonstrated that PND inhibits topoisomerase II
in a dose-dependent manner. Previous reports have shown that PND may act as a catalytic
inhibitor and a topoisomerase II poison in mammalian cells, depending upon exposure
concentration11. This demonstrates that PND’s activity as a topoisomerase inhibitor is not solely
seen in P. falciparum but also in mammalian cells, and our data support that the mechanism of
action by which PND causes cytotoxicity in cancer cells is through topoisomerase II inhibition
and activation of apoptosis.
To investigate if PND can exert its activity on cancer cells in-vivo, we utilized a severely
compromised immune-deficient mouse xenograft human cancer model to observe PND's effects
on experimentally implanted human breast cancer tumors. PND was administered orally on a
daily basis on mice implanted with MDA-MD-231 cells, and this treatment resulted in significant
inhibition of tumor growth over the course of 20 days. As expected from other PND-treatment
studies11,54, no noticeable side effects were observed, except for the skin's yellow coloration, most
prominently seen in ears and legs. Previous in-vivo studies using PND also reported increased
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yellow coloration as a side effect and indicate the total or partial recovery of tissue coloration
after a two-week recovery period11.
We performed combinational drug studies in vitro, where we observed the cytotoxic
effects of PND with other currently used, well-known FDA-approved anticancer drugs,
Cisplatin, Gemcitabine, MG132, Melphalan, Bortezomib, Doxorubicin, and two novel drugs
2350 and P2. It has been previously discussed that the combination of two or more drugs that
have different mechanisms of action is an alternative approach to increase the success of a drug
to be repurposed55. In the present study, only four drugs exhibited a synergistic effect with PND.
Gemcitabine, a nucleoside analog, cisplatin, a DNA intercalator, MG-132, and bortezomib both
proteasome inhibitors. We observed that while keeping a constant concentration of PND and
reducing the doses of the other drugs, there was a higher cytotoxic effect in breast cancer cells.
A pitfall in chemotherapy is drug resistance. In order to predict and assess PND’s
potential success as an anticancer drug we aimed to investigate its likelihood to elicit drug
resistance. MDA-MB-231 cells were used to generate PND- resistant cell lines. Over the course
of 4 months, MDA-MB-231 cells were treated with PND daily. Moreover, when assessing the
cell variants drug resistance, we observed a fold change that was indicative of no acquired
resistance. This may be due to PND’s ability to intercalate with DNA. Although no significant
resistance was elicited by prolonged PND treatment, we did observe a slight change in cell
morphology with treated cells becoming more elongated. Further analysis comparing cell length
and width between parental and resistant cell lines has to be done to confirm morphology
change.
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However, we observed PND’s cytotoxicity and selectivity in a Paclitaxel resistant
variant of MDA-MB-231. Paclitaxel is a microtubule-stabilizing drug that has been approved for
the treatment of breast cancer67. Since its use as a chemotherapeutic agent, paclitaxel resistance
has become a chemotherapy failure in breast cancer68. In our study, we show PND induces
cytotoxicity in the paclitaxel resistant cell line indicating that PND may be an effective treatment
for Paclitaxel resistant cancer cells.
5.1.2 Future Directions
The research presented in this dissertation is an initial step towards repurposing PND as
an anticancer drug. Additional long-term in-vivo studies possibly investigating PND’s activity in
different cancers can further enhance PND’s possibility of being repurposed. Furthermore,
clinical studies evaluating PND’s efficacy in cancer patients need to be conducted. Currently,
PND has been patented as an anticancer drug.
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